Galera Therapeutics, Inc.
GRTX
$0.0215
$0.00010.47%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -62.18% | -39.46% | -14.70% | -31.14% | -69.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -73.03% | -57.11% | -68.64% | -66.23% | -74.96% |
| Operating Income | 73.03% | 57.11% | 68.64% | 66.23% | 74.96% |
| Income Before Tax | 73.55% | 63.66% | 11.74% | 61.63% | 80.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.55% | 63.66% | 11.74% | 62.97% | 80.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.55% | 63.66% | 11.74% | 62.97% | 80.38% |
| EBIT | 73.03% | 57.11% | 68.64% | 66.23% | 74.96% |
| EBITDA | 73.11% | 57.14% | 67.28% | 66.24% | 74.97% |
| EPS Basic | 85.41% | 79.88% | 13.24% | 69.04% | 84.52% |
| Normalized Basic EPS | 85.44% | 79.92% | 80.84% | 76.28% | 84.52% |
| EPS Diluted | 85.41% | 79.88% | 13.24% | 69.04% | 84.52% |
| Normalized Diluted EPS | 85.44% | 79.92% | 80.84% | 76.28% | 84.52% |
| Average Basic Shares Outstanding | 81.10% | 81.10% | 1.79% | 19.60% | 26.74% |
| Average Diluted Shares Outstanding | 81.10% | 81.10% | 1.79% | 19.60% | 26.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |